Network Systems Biology for Drug Discovery

Systems biology provides a platform for integrating multiple components and interactions underlying cell, organ, and organism processes in health and disease. Beyond traditional approaches focused on individual molecules or pathways, bioinformatic network analysis of high‐throughput data sets offers an opportunity for integration of biological complexity and multilevel connectivity. Emerging applications in rational drug discovery range from targeting and modeling disease‐corrupted networks to screening chemical or ligand libraries to identification/validation of drug–target interactions for improved efficacy and safety.

[1]  L. Bertalanffy.  AN OUTLINE OF GENERAL SYSTEM THEORY , 1950, The British Journal for the Philosophy of Science.

[2]  A. Hodgkin,et al.  A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.

[3]  D. Noble.  Cardiac Action and Pacemaker Potentials based on the Hodgkin-Huxley Equations , 1960, Nature.

[4]  Mihajlo D. Mesarovic,et al.  Systems Theory and Biology , 1968 .

[5]  M. Savageau.  Biochemical Systems Analysis: A Study of Function and Design in Molecular Biology , 1976 .

[6]  Joseph Christmas,et al.  The Decade and beyond , 1991 .

[7]  Albert,et al.  Emergence of scaling in random networks , 1999, Science.

[8]  Albert-László Barabási,et al.  Error and attack tolerance of complex networks , 2000, Nature.

[9]  Leroy Hood,et al.  Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. , 2004, Journal of proteome research.

[10]  Leroy Hood,et al.  The impact of systems approaches on biological problems in drug discovery , 2004, Nature Biotechnology.

[11]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[12]  A. Terzic,et al.  ATP-sensitive K+ channel channel/enzyme multimer: metabolic gating in the heart. , 2005, Journal of molecular and cellular cardiology.

[13]  A. Giuliani,et al.  Functional essentiality from topology features in metabolic networks: A case study in yeast , 2005, FEBS letters.

[14]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[15]  D. K. Arrell,et al.  Pharmacoproteomics: Advancing the Efficacy and Safety of Regenerative Therapeutics , 2007, Clinical pharmacology and therapeutics.

[16]  Pei Yee Ho,et al.  Multiple High-Throughput Analyses Monitor the Response of E. coli to Perturbations , 2007, Science.

[17]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[18]  P. Silver,et al.  Molecular Systems Biology in Drug Development , 2007, Clinical pharmacology and therapeutics.

[19]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[20]  U. Sauer,et al.  Getting Closer to the Whole Picture , 2007, Science.

[21]  T. Pawson,et al.  Network medicine , 2008, FEBS letters.

[22]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[23]  W-C Hwang,et al.  Identification of Information Flow‐Modulating Drug Targets: A Novel Bridging Paradigm for Drug Discovery , 2008, Clinical pharmacology and therapeutics.

[24]  Timothy J. Nelson,et al.  Stem Cells: Biologics for Regeneration , 2008, Clinical pharmacology and therapeutics.

[25]  D. K. Arrell,et al.  Cardioinductive Network Guiding Stem Cell Differentiation Revealed by Proteomic Cartography of Tumor Necrosis Factor α‐Primed Endodermal Secretome , 2008, Stem cells.

[26]  A. Terzic,et al.  Bioinformatic Networks: Molecular Reticles for Pinpointing Pharmacological Target Selection , 2008, Clinical pharmacology and therapeutics.

[27]  A. Terzic,et al.  Therapeutic Targeting: A Crucible for Individualized Medicine , 2008, Clinical pharmacology and therapeutics.

[28]  D. Noble,et al.  Systems biology and the virtual physiological human , 2009, Molecular systems biology.

[29]  D. K. Arrell,et al.  ATP-sensitive K+ channel knockout induces cardiac proteome remodeling predictive of heart disease susceptibility. , 2009, Journal of proteome research.

[30]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[31]  M. Vidal,et al.  Edgetic perturbation models of human inherited disorders , 2009, Molecular systems biology.

[32]  F. Markowetz,et al.  Systems-level dynamic analyses of fate change in murine embryonic stem cells , 2009, Nature.

[33]  Gary D Bader,et al.  How to visually interpret biological data using networks , 2009, Nature Biotechnology.

[34]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[35]  Albert-László Barabási,et al.  Scale-Free Networks: A Decade and Beyond , 2009, Science.

[36]  F. Fernández‐Avilés,et al.  Delivery of Biologics in Cardiovascular Regenerative Medicine , 2009, Clinical pharmacology and therapeutics.

[37]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[38]  C. Runowicz,et al.  The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. , 2010, Gynecologic oncology.

[39]  Zhong Wang,et al.  Modular pharmacology: the next paradigm in drug discovery , 2012, Expert opinion on drug discovery.